**Search strategies:** Tan MH, Iyengar R, Mizokami-Stout K, et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. *Clin Diabetes Endocrinol*. 2019;5:1. Published 2019 Jan 22. doi:10.1186/s40842-018-0073-4

**Ovid MEDLINE; Ovid MEDLINE In-Process & Other Non-Indexed Citations; Ovid MEDLINE Epub Ahead of Print**

1. exp endocrine system diseases/ or (acth or adrenocortic\* or dmt1 or dm t1 or diabet\* or endocrin\* or grave\* or hyperthyroid\* or hypoadrenal\* or hypophysit\* or hypothyroid\* or neuroendocrin\* or parathyroid\* or polyendocrino\* or t1 dm or t1dm or thyroid\* or thyrotoxic\* or (adrenal adj2 (deficienc\* or insufficienc\*))).tw

2. (checkpoint\* adj4 (block\* or immun\* or inhibit\* or therap\*)).tw. or (checkpoint\*.tw. and (exp immunotherapy/ or exp \*cell death/)) or (anti-pd-1 or anti-pd-L1 or atezolizumab or avelumab or bavencio or durvalumab or duvalumab or imfinzi or ipilimumab or keytruda\* or lambrolizumab or nivolumab or opdivo or pembrolizumab or pidilizumab or strentarga or tecentriq or tremelimumab or yervoy).tw. or (checkpoint\* and ((program\* adj4 death\*) or necrocytosis)).tw. or ((block\* or inhibit\*) adj3 (ctla-4 or ctla4 or pd1 or pd 1 or pdcd1\* or pdL1 or pd-L1 or pd-L-1)).tw. or (checkpoint\* and (ctla-4 or ctla4)).tw.

3. and/1-2 not (exp animals/ not exp humans/) not (editorial or comment).pt

**Embase.com** (no conference abstracts)

#1 'endocrine disease'/exp/mj OR acth:ab,ti OR adrenocortic\*:ab,ti OR dmt1:ab,ti OR 'dm t1':ab,ti OR diabet\*:ab,ti OR endocrin\*:ab,ti OR grave\*:ab,ti OR hyperthyroid\*:ab,ti OR hypoadrenal\*:ab,ti OR hypophysit\*:ab,ti OR hypothyroid\*:ab,ti OR neuroendocrin\*:ab,ti OR parathyroid\*:ab,ti OR polyendocrino\*:ab,ti OR 't1 dm':ab,ti OR t1dm:ab,ti OR thyroid\*:ab,ti OR thyrotoxic\*:ab,ti OR (adrenal NEAR/2 (deficienc\* OR insufficienc\*)):ab,ti

#2 'checkpoint kinase inhibitor'/exp OR (checkpoint\* NEAR/4 (block\* OR immun\* OR inhibit\* OR therap\*)):ti,ab OR 'anti-pd-1':ti,ab OR 'anti-pd-l1':ti,ab OR atezolizumab:ti,ab OR avelumab:ti,ab OR bavencio:ti,ab OR durvalumab:ti,ab OR duvalumab:ti,ab OR imfinzi:ti,ab OR ipilimumab:ti,ab OR keytruda:ti,ab OR lambrolizumab:ti,ab OR nivolumab:ti,ab OR opdivo:ti,ab OR pembrolizumab:ti,ab OR pidilizumab:ti,ab OR strentarga:ti,ab OR tecentriq:ti,ab OR tremelimumab:ti,ab OR yervoy:ti,ab OR (checkpoint\*:ti,ab AND ((program\* NEAR/4 death\*):ti,ab OR necrocytosis:ti,ab)) OR ((block\* OR inhibit\*) NEAR/2 (‘ctla-4’ OR ctla4 OR pd1 OR 'pd 1' OR pdcd1\* OR pdl1 OR 'pd-l1' OR 'pd-l-1')):ab,ti OR (checkpoint\* AND (‘ctla-4’ OR ctla4)):ti,ab

#3 #1 AND #2 NOT (note:it OR editorial:it OR ‘conference paper’:it OR ‘conference abstract’:it) NOT ([animals]/lim NOT [humans]/lim)

**Embase.com** (conference abstracts)

('endocrine disease'/exp/mj OR acth:ti OR adrenocortic\*:ti OR dmt1:ti OR 'dm t1':ti OR diabet\*:ti OR endocrin\*:ti OR grave\*:ti OR hyperthyroid\*:ti OR hypoadrenal\*:ti OR hypophysit\*:ti OR hypothyroid\*:ti OR neuroendocrin\*:ti OR parathyroid\*:ti OR polyendocrino\*:ti OR 't1 dm':ti OR t1dm:ti OR thyroid\*:ti OR thyrotoxic\*:ti OR ((adrenal NEAR/1 (deficienc\* OR insufficienc\*)):ti)) AND ('checkpoint kinase inhibitor'/exp/mj OR ((checkpoint\* NEAR/3 (block\* OR immun\* OR inhibit\* OR therap\*)):ti) OR atezolizumab:ti OR avelumab:ti OR bavencio:ti OR durvalumab:ti OR duvalumab:ti OR imfinzi:ti OR ipilimumab:ti OR keytruda:ti OR lambrolizumab:ti OR nivolumab:ti OR opdivo:ti OR pembrolizumab:ti OR pidilizumab:ti OR strentarga:ti OR tecentriq:ti OR tremelimumab:ti OR yervoy:ti) AND ('conference abstract':it OR 'conference paper':it)

**Cochrane Central Register of Controlled Trials**

1. [mh "endocrine system disease"] or (acth or adrenocortic\* or dmt1 or "dm t1" or diabet\* or endocrin\* or grave\* or hyperthyroid\* or hypoadrenal\* or hypophysit\* or hypothyroid\* or neuroendocrin\* or parathyroid\* or polyendocrino\* or "t1 dm" or t1dm or thyroid\* or thyrotoxic\* or (adrenal NEAR/2 (deficienc\* or insufficienc\*))):ab,ti

2. (checkpoint\* NEAR/4 (block\* or immun\* or inhibit\* or therap\*)):ab,ti or (checkpoint\*:ab,ti and ([mh immunotherapy] or [mh "cell death"])) or ("anti-pd-1" or "anti-pd-L1" or atezolizumab or avelumab or bavencio or durvalumab or duvalumab or imfinzi or ipilimumab or keytruda\* or lambrolizumab or nivolumab or opdivo or pembrolizumab or pidilizumab or strentarga or tecentriq or tremelimumab or yervoy):ab,ti or (checkpoint\* and ((program\* NEAR/4 death\*) or necrocytosis)):ab,ti or ((block\* or inhibit\*) AND ("ctla-4" or ctla4 or pd1 or "pd 1" or pdcd1\* or pdL1 or "pd-L1" or "pd-L-1")):ab,ti or (checkpoint\* and ("ctla-4" or ctla4)):ti,ab

3. #1 and #2

**Web of Science**

1. TS=((checkpoint\* NEAR/3 (block\* OR inhibit\* OR immun\* OR therap\*)) OR "anti-pd-1" OR atezolizumab OR avelumab OR bavencio OR durvalumab OR duvalumab OR imfinzi OR ipilimumab OR keytruda\* OR lambrolizumab OR nivolumab OR opdivo OR pembrolizumab OR pidilizumab OR strentarga OR tecentriq OR tremelimumab OR yervoy OR (checkpoint\* AND ((program\* NEAR/4 death\*) OR necrocytosis)) OR ((block\* OR inhibit\*) NEAR/3 (pd1 OR "pd 1" OR pdcd1\* OR pdL1 OR "pd-L1" OR "pd-L-1")))

2. TS=((acth OR adrenocortic\* OR dmt1 OR "dm t1" OR diabet\* OR endocrin\* OR grave\* OR hyperthyroid\* OR hypoadrenal\* OR hypophysit\* OR hypothyroid\* OR neuroendocrin\* OR parathyroid\* OR polyendocrino\* OR "t1 dm" OR t1dm OR thyroid\* OR thyrotoxic\* OR (adrenal NEAR/2 (deficienc\* OR insufficienc\*))))

3. #1 AND #2